Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Cancer immunotherapy Stories

2010-10-20 12:07:00

SEATTLE, Oct. 20 /PRNewswire/ -- Adaptive TCR Technologies, a biotech firm based in Seattle, WA, announced today the release of its immunoSEQ(TM) profiling service and immunoSEQ Analyzer(TM) bioinformatics software platform. Together, these tools provide researchers and clinicians the ability to profile and monitor the adaptive immune system at a level of detail that has never before been possible. "ImmunoSEQ represents one of the first specific applications of next-generation sequencing...

2010-10-20 06:30:00

SEATTLE, Oct. 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at Cancer Immunotherapy: A Long Awaited Reality conference taking place October 21, 2010 at the New York Academy of Medicine in New York City. The conference will be hosted by MD Becker Partners and BioBusiness.TV. There will be a corresponding live webcast of the conference, which can be accessed by visiting http://www.mdbpartners.com/vaccine. About Dendreon...

2010-10-18 07:12:00

DURHAM, N.C., Oct. 18 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present an overview of its Arcelis(TM) dendritic cell-based immunotherapy at 3:30 p.m. EDT on Oct. 21 at the inaugural Cancer Immunotherapy Conference in New York. In addition, Charles Nicolette, Ph.D., the company's chief scientific officer and vice president of research and development, will participate in a panel discussion titled...

2010-10-14 05:00:00

BETHESDA, Md., Oct. 14 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) today announced that the company will be presenting at the Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:00 p.m. EDT on October 21, 2010, at the New York Academy of Medicine in New York. Dr. Marnix Bosch, Chief Technical Officer, will provide an overview of the Company's DCVax® technology and unprecedented long-term clinical trial...

2010-09-30 19:21:09

Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in...

2010-09-28 07:00:00

COLUMBIA, Md., Sept. 28 /PRNewswire/ -- A&G Pharmaceutical announced today that it has received $1.2 million in Phase II Small Business Innovation Research (SBIR) funding from the National Cancer Institute (NCI) for the program, "Novel Targeted Therapy for Breast Cancer," focused on the development of a neutralizing therapeutic antibody against a novel cancer-associated protein, GP88. GP88 is a glycoprotein that plays a critical role in the development of human cancers, including...

2010-09-24 07:00:00

DURHAM, N.C., Sept. 24 /PRNewswire/ -- Argos Therapeutics today announced that results from its Arcelis(TM) immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago. The study is an open-label Phase 2 trial that enrolled 25 patients with newly diagnosed metastatic clear cell RCC. Post-nephrectomy, subjects received sunitinib and then concomitant...

2010-09-10 11:45:04

Cancer immunotherapy calls for revised clinical endpoints that differ from those used for chemotherapy, according to an article published online September 8 in The Journal of the National Cancer Institute. Unlike chemotherapy, which acts directly on tumors, cancer immunotherapies exert their effects on the immune system, which may delay or change response patterns, perhaps owing to the dynamics of the immune system itself. For example, initial tumor burden may increase due to lymphocytic...

2010-08-23 07:51:11

(Ivanhoe Newswire) -- A team of engineers has devised a way to deliver cancer-fighting drugs by smuggling them on the backs of the immune cells sent in to fight the tumor. The drugs reach only their intended targets, greatly reducing the risk to the patient. The new approach could dramatically improve the success rate of immune-cell therapies, which hold promise for treating many types of cancer, according to senior author Darrell Irvine, associate professor of biological engineering and...

2010-08-17 07:00:00

SAN DIEGO, Aug. 17 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP). Under the SNAP procedures, both initial and follow-on...